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Abstract: Capuramycin and a few semisynthetic derivatives 
have shown potential as anti-tuberculosis antibiotics. 
To understand their mechanism of action and structure-
activity relationships a 3D-QSAR and molecular docking 
studies were performed. A set of 52 capuramycin derivatives 
for the training set and 13 for the  validation set was used. 
A highly predictive MFA model was obtained with cross-
validated q2 of 0.398, and non-cross validated partial least-
squares (PLS) analysis showed a conventional r2 of 0.976 
and r2pred of 0.839. The model has an excellent predictive 
ability. Combining the 3D-QSAR and molecular docking 
studies, a number of new capuramycin analogs with 
predicted improved activities were designed. Biological 
activity tests of one analog showed useful antibiotic 
activity against Mycobacterium smegmatis MC2 155 and 
Mycobacterium tuberculosis H37Rv. Computer-aided 
molecular docking and 3D-QSAR can improve the design 
of new capuramycin antimycobacterial antibiotics.1
Keywords: Capuramycin analogue; antimycobacterial; 
3D-QSAR; molecular docking; drug design
# The authors contributed equally to this work.
1 Introduction
The dramatic increase in multidrug resistant (MDR) 
bacteria is now a global threat to human health [1,2]. 
Development of novel compounds with a new mechanism 
to fight MDR strains is required. Peptidoglycan is a unique 
feature in bacteria cell walls, without an equivalent in 
eukaryotes [3]. Enzymes involved in its biosynthesis are 
ubiquitous and essential to bacterial growth. In particular, 
translocase I (MraY) [4], which catalyzes the first membrane 
step of peptidoglycan biosynthesis [5,6], has been little 
exploited due to its transmembrane location [7], and it is 
not the target of any antibiotics in clinical use. The crystal 
structure of MraY from Aquifex aeolicus (MraYAA) was 
recently solved at 3.3Å by Chung and colleagues [8], and 
several inhibitors of this enzyme are known. These make 
the discovery of new potent inhibitors possible.
Capuramycin, originally isolated from the culture 
broth of Streptomyces griseus 446-S3, and its methylated 
derivative, A-500359A (Figure 1) were found while 
screening for new antibiotics with translocase-I inhibitory 
activity. These capuramycin-related compounds include 
a series of congeners termed A-500359s and the 2-O-
carbamoylated variants A-503083s. Capuramycin and 
A-500359A inhibit translocase I with IC50 values of 10 
ng/mL (18nM) and 10 ng/mL (17 nM), respectively [9]. 
The MIC values for capuramycin and A-500359A against 
Mycobacterium smegmatis SANK75075 are 12.5 and 6.25 
mg/mL, respectively. A series of acylated derivatives 
of capuramycin and analogues having a variety of 
substituents in place of the azepan-2-one moiety were 
synthesized and their antimycobacterial activities tested 
by Sankyo Co., Ltd. [10,11]. Although narrow in spectrum, 
bioactivity studies have revealed their potential utility as 
anti-tuberculosis antibiotics.
Computer-aided drug design has been extensively 
applied in the area of modern drug discovery [12,13]. 
QSAR analysis generates models correlating biological 
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activity and the physicochemical properties of a series 
of molecules. A validated 3D-QSAR model not only helps 
understanding the structure-activity relationships, but 
also provides insight into lead molecules for further 
development [14].
Our goal was to perform a 3D-QSAR [15] study to explore 
the relationship between the structure of capuramycin 
analogues and their MraY inhibitory activity. The contour 
maps derived from the models provide an insight into the 
steric and electrostatic requirements for ligand binding. 
By molecular docking analyses [16] we sought active 
site structural features and details of protein–inhibitor 
interactions to design new potential inhibitors.
2 Experimental Procedure
2.1 Preparation of Receptor Structures and 
Databases
All work was performed using Discovery Studio 3.5 
software (Accelrys, San Diego, CA, USA) on a Dell Precision 
TM T5500 computer.
The crystal structure of MraY (PDB ID 4J72) was downloaded 
from the RCSB Brookhaven Protein Data Bank [17,18].
A total of 65 capuramycin derivatives were used. 
Their structures and inhibitory activities (measured under 
similar conditions) are shown in Table 1 [10,11]. The IC50 
values were converted to pIC50 (-log IC50) values and used 
as dependent variables for 3D-QSAR analysis. The dataset 
was divided into a training set of 52 compounds (80% of 
the original data) to derive the models, and a test set of the 
remaining 13 compounds (20%) to determine the external 
predictivity of the resulting models, using the Generate 
Training and Test Data module. 
2.2 3D-QSAR models
A quantitative structure-activity relationship (QSAR) is one 
of the most important chemometric applications, giving 
information useful for the design of new compounds 
acting on a target [12]. A proper alignment of the 
structures is critical for obtaining a valid 3D-QSAR [19,20]. 
An automatic alignment based on the common structure 
was performed by Align to Selected Structure. The most 
active compound (27) with the minimum IC50 was used 
as the alignment template. Figure 2A shows the common 
alignment scaffold while Figure 2B shows the alignment 
conformations of all training set molecules.
Regression models built from whole-molecular 
steric and electrostatic fields can be useful for predicting 
activity and for visualizing favorable and unfavorable 
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Capuramycin, A-500359 B (1) (R1=H, R2=H)
                          A-500359 A (2) (R1=H, R2=Me)
               A-503083 B (3) (R1=CONH2, R2=H)
               A-503083 A (4) (R1=CONH2, R2=Me)
Figure 1: Capuramycin and its congeners.
Figure 2: (A) Common scaffold used for alignment. (B) Structural 
alignment of the training set derivatives.
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Table 1: Experimental and 3D-QSAR predicted MraY inhibition activities of capuramycin derivatives.
O
R
O
OH
OH
O
CONH2
O N
NH
O
OMeO OH
Compound R IC50 (nM) pIC50 DS -CDOCKER_ INTERACTION_ 
ENERGYpIC50 Residual
Capuramycin 18 -1.255 -1.492 0.237 88.45
A-500359A 17 -1.230 -1.373 0.143 79.02
3 Me(CH2)3NH– 545 -2.736 -2.570 -0.166 82.38
4 Me(CH2)5NH– 55 -1.740 -1.752 0.012 73.76
5 Cyclohexyl-NH– 56 -1.748 -1.830 0.082 76.48
6 Cycloheptyl-NH– 49 -1.690 -1.650 -0.040 81.22
7 EtO(CH2)3NH– 257 -2.410 -2.402 -0.008 80.69
8 MeS(CH2)3NH– 128 -2.107 -2.081 -0.026 77.02
9 H2N(CH2)2NH– 1198 -3.078 -2.993 -0.085 82.05
10 Me(CH2)9NH– 435 -2.638 -2.560 -0.078 80.83
11 Ph(CH2)2NH– 37 -1.568 -1.502 -0.066 78.87
12 4-Me–Ph(CH2)2NH– 59 -1.771 -1.905 0.134 77.90
*13 4-MeO–Ph(CH2)2NH– 68 -1.833 1.881 0.048 81.73
14 3-MeO–Ph(CH2)2NH– 32 -1.505 -1.624 0.119 79.22
15 3,4-(MeO)2–Ph(CH2)2NH– 40 -1.602 -1.491 -0.111 83.39
*16 4-F–Ph(CH2)2NH– 38 -1.580 -1.777 0.197 78.57
17 2-Cl–Ph(CH2)2NH– 47 -1.672 -1.881 0.209 86.69
*18 3-Cl–Ph(CH2)2NH– 34 -1.531 -1.751 0.220 70.64
19 2,4-Cl2–Ph(CH2)2NH– 30 -1.477 -1.487 0.010 84.91
*20 4-HO–Ph(CH2)2NH– 104 -2.017 -1.708 -0.309 77.93
21 PhCH2NH– 219 -2.340 -2.502 0.162 75.05
*22 2-Me–PhCH2NH– 890 -2.949 -1.952 -0.997 79.24
23 4-Me–PhCH2NH– 2135 -3.329 -3.254 -0.075 79.67
24 4-F–PhCH2NH– 353 -2.548 -2.538 -0.010 85.26
25 2-MeO–PhCH2NH– 484 -2.685 -2.788 0.103 82.13
26 4-MeO–PhCH2NH– 1211 -3.083 -3.114 0.031 83.60
27 PhNH– 12 -1.079 -1.107 0.028 81.54
28 3-Me–PhNH– 14 -1.146 -1.086 -0.060 84.17
29 4-Me–PhNH– 24 -1.380 -1.464 0.084 78.39
30 2,4-Me2–PhNH– 107 -2.029 -1.909 -0.120 78.10
31 2-Et–PhNH– 96 -1.982 -2.032 0.050 87.09
32 4-Et–PhNH– 36 -1.556 -1.354 -0.202 78.15
33 4-(Me(CH2)5)–PhNH– 259 -2.413 -2.280 -0.133 82.86
*34 4-CF3–PhNH– 50 -1.699 -1.823 0.124 80.29
*35 2-MeO–PhNH– 55 -1.740 -1.912 0.172 83.84
36 2-EtO–PhNH– 64 -1.806 -1.915 0.109 86.01
*37 3-F–PhNH– 18 -1.255 -1.610 0.355 73.15
*38 4-F–PhNH– 67 -1.826 -1.583 -0.243 72.47
39 2,3-F2–PhNH– 23 -1.362 -1.073 -0.289 76.71
*40 2,4-F2–PhNH– 26 -1.415 -1.663 0.248 81.59
41 3,4-F2–PhNH– 16 -1.204 -1.160 -0.044 80.15
42 4-Cl–PhNH– 32 -1.505 -1.601 0.096 78.52
43 4-Br–PhNH– 33 -1.519 -1.502 -0.017 88.96
44 2-NO2–PhNH– 69 -1.839 -1.563 -0.276 83.68
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interactions. The 3D-QSAR module came from MFA 
(molecular field analysis) in Cerius 2. MFA computes 
the steric and electrostatic interactions of a series of 
molecules using probes in a regularly spaced grid [21]. 
The PLS regression  performed generalizes and combines 
features from principal component analysis (PCA) and 
multiple regression. The PLS “leave-one-out” method 
[22] was used for cross validation to obtain the q2 value 
and the optimum number of components to be used in 
the final QSAR models. The cross-validated q2 indicates 
the predictive power of the analysis [23]; q2 > 0.3 indicates 
the probability of chance correlation is less than 5% [24]. 
The non-cross-validated PLS analysis of these compounds 
was repeated with the optimum number of components as 
determined by the cross-validated analysis [25].
O
H
N
O
OH
OH
O
CONH2
O N
NH
O
OMeO O
HN
O
O
X(CH2)nH
R
Compound R X n IC50 (nM) pIC50 DS -CDOCKER_ INTERACTION_ 
ENERGYpIC50 Residual
45 H CH2 5 59 -1.771 -1.726 -0.045 75.35
46 H CH2 7 254 -2.405 -2.312 -0.093 88.70
47 H CH2 8 415 -2.618 -2.404 -0.214 92.29
48 Me CH2 3 36 -1.556 -1.316 -0.240 82.10
49 Me CH2 4 63 -1.799 -1.774 -0.025 90.11
50 Me CH2 5 65 -1.813 -2.053 0.240 86.15
51 Me CH2 6 268 -2.428 -2.673 0.245 87.19
52 Me CH2 7 235 -2.371 -2.421 0.050 87.40
53 Me CH2 8 746 -2.873 -2.614 -0.259 82.00
*54 Me CH2 10 2876 -3.459 -2.460 -0.999 57.23
55 Me CH2 12 5675 -3.754 -3.371 -0.383 57.41
*56 Me CH2 13 2974 -3.473 -2.340 -1.133 61.71
57 Me CH2 14 524 -2.719 -2.698 -0.021 89.19
58 Me O 6 183 -2.262 -2.463 0.201 91.69
59 Me O 7 276 -2.441 -2.642 0.201 86.13
60 Me O 8 677 -2.831 -2.757 -0.074 84.43
*61 Me O 9 1859 -3.269 -2.634 -0.635 95.46
O
H
N
O
OH
OH
O
CONH2
O N
NH
O
OMeO O
HN
O
R
(CH2)nH
Compound R n IC50 (nM) pIC50 DS -CDOCKER_ INTERACTION_ 
ENERGYpIC50 Residual
62 Me 5 77 -1.886 -2.012 0.126 73.68
63 Me 6 60 -1.778 -2.403 0.625 76.64
64 Me 8 216 -2.334 -2.470 0.136 81.75
65 Me 10 885 -2.947 -2.677 -0.270 87.06
* test molecules
ContinuedTable 1: Experimental and 3D-QSAR predicted MraY inhibition activities of capuramycin derivatives.
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2.3 Molecular Docking
Computational docking is useful to probe the interaction 
of a receptor with its ligand and reveal their binding 
mechanism; it is a module where two or more molecules 
recognize each other by geometry and energy matching. 
It can offer insight into the protein–inhibitor interactions 
and the active site structural features [26-30]. Molecular 
docking computations were carried out using the CDOCKER 
[31-35] program employing the CHARMm [36] force field 
using the consistent force field ligand partial charge 
method to validate the ideas on design of these inhibitors. 
For ligand preparation, duplicate structures were removed 
and options for ionization change, tautomer generation, 
isomer generation, Lipinski filter and 3D generator were 
set true. For enzyme preparation, the whole enzyme 
was selected, waters removed and hydrogen atoms were 
added. The pH of the protein was set in the range 6.5-8.5. 
The enzyme was defined as a total receptor; its binding site 
defined by selecting the amino acids Asp117, Asp118, Asp265 
and His324 (mutational studies showed these residues are 
important for catalysis) to generate a 15 Å radius sphere 
by the operation of Define and Edit Binding Site. Docking 
of compounds into MraY with CDOCKER was done using 
the default parameters. Energy was minimized until an 
energy gradient of 0.01 was reached. The configuration 
with the highest -CDOCKER_INTERACTION_ENERGY was 
chosen to analyze the binding features.
Ethical approval: The conducted research is not 
related to either human or animals use.
3 Results and Discussion
3.1 3D-QSAR analysis
3.1.1 MFA statistical analysis
The MFA model was constructed using 52 capuramycin 
derivatives as the training set. This model was used to 
predict activities of the test set of 13 compounds. The 
models were generated with 3 optimal components giving 
a cross-validated q2 of 0.398, signifying good predictive 
ability. The calculated activities, predicted activities and 
residuals in the training and test sets are listed in Table 1. 
The predicted pIC50 values are within statistically tolerable 
error of the experimental data. The non-cross validated 
r2 (0.976) suggested good model linearity. The predictive 
correlation coefficient r2pred was 0.839; comparisons of the 
predicted and experimental values are in Figure 3.
The resulting 3D-QSAR model is statistically significant 
and reliable, and was used to design novel capuramycin 
derivatives with improved MraY inhibitory activity.
3.1.2 MFA contour plots
Contour maps provide information on factors affecting 
compound activity. This is particularly important when 
designing a new drug by changing the structural features 
contributing to the interaction between the ligand and the 
Figure 3: Predicted versus experimental pIC50 values; (A) training 
set; (B) test set.
Figure 4: MFA contour maps for steric (A) and electrostatic (B) effects with capuramycin as the reference molecule.
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active site. Therefore, it is essential routine in designing 
and evaluating novel inhibitors.
The analysis contour plots are shown in Figure 4. In 
the steric contour map, green regions indicate areas where 
steric bulk is predicted to enhance the inhibition activity, 
and yellow indicates regions where bulk is predicted to 
decrease it. In the electrostatic contour map, blue regions 
denote areas where electropositive groups are predicted 
to improve inhibition affinity, while red regions represent 
areas where electronegative groups are predicted to 
improve it. Capuramycin was embedded into the maps 
to illustrate its relationships to the inhibitors’ steric and 
electrostatic properties.
In Figure 4A, yellow regions located near the 
capuramycin azepan-2-one group indicate that large 
substituents around this position might decrease the 
activity. This is supported by the observation that 
compounds 3 and 10 with large alkyl groups there 
displayed low activities. The other major yellow contour 
was found around the nucleoside 2’-OH, implying that 
large substituents in this position can decrease activity. 
This may be why acyl/alkoxycarbonyl derivatives 45-
65 around the 2’- position showed less potency than 
compounds without substituents there. A major green 
contour surrounding the sugar hydroxyl suggests that 
bulky substituents there could improve the inhibitory 
potency.
In Figure 4B, the zepan-2-one moiety of capuramycin 
is embedded in a large red region and the other two red 
contours were observed around this position, indicating 
that negatively charged substituents there favored activity. 
In support, compound 27 with a phenyl substituent there 
possessed the highest potency. Interestingly, though 
compounds 11-21 having phenethyl-type substituents and 
compounds 22-27 having benzyl-type substituents were 
all substituted by electronegative groups, they were less 
potent than phenyl analogues. This may be due to the 
substituents’ steric conformation. In addition, some blue 
contours favoring positively charged substitution was 
observed around the nucleoside 2’-OH, suggesting that an 
electropositive substituent at this position was favored. 
However, inhibitory activity was related to the size of alkyl 
chain as well. As the alkyl chain became longer activity 
decreased, as shown by compounds 49-57.
3.2 Docking analysis
The CDOCKER docking algorithm uses the CHARMm 
family of force fields and offers the advantages of full 
ligand flexibility (including bonds, angles, and dihedrals) 
and reasonable computation times [37]. Twenty binding 
configurations per ligand were obtained, and the 
configuration with the highest CDOCKER_INTERACTION_
ENERGY was taken as the ligand–receptor interaction, 
which was then compared manually. The most active 
compound 27 and capuramycin bound in similar 
conformations. The end of each entered the deep and 
narrow catalytic pocket (Figure 5A). This is consistent with 
the 3D-QSAR finding that a bulky group was disfavored 
there. In Figure 5B we see that each can form hydrogen 
bonds with Asp118, which is the key residue for catalysis. 
Figure 5: Docking of capuramycin (green) and compound 27 (cyan) with MraY. (A) The protein is represented as a hydrophobicity surface 
complexed with capuramycin and compound 27. Brown and blue shades represent hydrophobic and hydrophilic regions respectively. (B) 
Docking of capuramycin and compound 27 with the active site. The H-bonds between MraY and the two compounds are shown as green 
dashed lines.
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They have the high CDOCKER_INTERACTION_ENERGY 
of 81.54 and 88.45 kcal/mol respectively, which explains 
their greater affinities (IC50 = 12nM, 18nM) than the other 
derivatives.
Although compound 61 with medium potency has the 
highest -CDOCKER_INTERACTION_ENERGY, there is 
no precise correlation between this parameter and IC50, 
because experimental IC50 values depend on a number of 
events in addition to target inhibition.
3.3 Design of new molecules based on 
3D-QSAR 
Based on the contour maps, the models were used to 
propose new capuramycin derivatives by substituent 
modification around the azepan-2-one (Table 2). Some 
modifications were also tried at the nucleoside 2’-OH and 
the sugar hydroxyl. These resulted in new capuramycin 
analogs with predicted improved activities. The activity 
may be further enhanced through modification. 
3.4 Synthesis of S1
All reagents were purchased from commercial suppliers 
and used as received unless otherwise indicated. Reaction 
courses were monitored by LC-MS. 1H-NMR and 13C-NMR 
spectra were taken on a Bruker spectrometer using TMS 
internal standard and D2O solvent. Mass spectra were 
measured on an Agilent 1100 series.
Procedure for the preparation of S1: (2R,3R,4R,5S)-5-
((S)-2-amino-1-(((2S,3S,4S)-6-((benzyloxy)carbamoyl)-
3,4-dihydroxy-3,4-dihydro-2H-pyran-2-yl)oxy)-2-
oxoethyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)-4- methoxytetrahydrofuran-3-yl carbamate
To a solution of A-503083F (52.5mg, 0.1mmol) in DMF 
(10ml), DIPEA (39mg, 0.3mmol), EDCI (28.75mg, 0.15mmol) 
and HOBT (13.5mg, 0.1mmol) were added. After stirring 
for 30min, o-benzylhydroxylamine (61.5mg, 0.5mmol) 
was added and the mixture stirred at room temperature 
overnight, after which the reaction mixture was poured 
into water (100ml), and extracted with EA (3 × 20ml). 
The aqueous phase was freeze-dried to obtain the crude 
reaction mixture. Further purification was performed by 
HPLC using a C-18 reverse-phase semi-preparative column, 
affording S1 as a white solid (15mg, 26%). 1H NMR (400 
MHz, D2O) δ 7.63 (d, J=8.1 Hz, 1H), 7.45-7.38 (m, 5H), 5.89 
(dd, J=2.5, 1.7 Hz, 1H), 5.86-5.81 (m, 2H), 5.28 (d, J=3.2 Hz, 
1H), 5.18 (dd, J=5.3, 4.1 Hz, 1H), 4.89 (s, 2H), 4.60 (d, J=2.7 
Hz, 1H), 4.48 (dd, J=4.5, 2.5 Hz, 1H), 4.39 (dd, J=6.1, 2.6 Hz, 
1H), 4.14-4.10 (m, 1H), 3.91 (t, J=5.7 Hz, 1H), 3.27 (s, 3H). 13C 
NMR (100 MHz, D2O with methanol as standard) δ 172.5, 
156.9, 150.9, 141.5, 140.4, 134.3, 129.6, 129.5, 129.1, 128.5, 
109.9, 102.1, 98.8, 88.6, 81.6, 78.3, 77.5, 75.1, 73.3, 64.5, 61.5, 
58.2. HRMS (ESI): C25H29N5O13+H+, Calc: 608.1835, Found: 
608.1840.
3.5 Antimycobacterial activity
S1 was evaluated for in vitro activity against M. smegmatis 
MC2 155 and M. tuberculosis H37Rv according to the 
published method [39]. It had a significantly better MIC 
(7.7μM) than the parent 3 (60μM) against M. smegmatis 
MC2 155. It had relatively good anti-TB activity against 
Mycobacterium tuberculosis H37Rv (15 μM), comparable to 
2 (14 μM).
Table 2: New molecules designed based on the MFA contour.
Compound Structure Predicted 
activity 
(pIC50)
S1
O
MeO OCONH2
CONH2
OO
OH
OH
N NH
O
O
H
N
O
O
-1.168
S2
O
MeO OCONH2
CONH2
OO
OH
OH
N NH
O
O
H
N
ON
-1.398
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O
MeO OCONH2
CONH2
OO
OH
OH
N NH
O
O
H
N
O
HN
O
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S4
O
MeO OCONH2
CONH2
OO
OH
OH
N NH
O
O
H
N
OO
-1.402
S5
O
H
N
O
O
O
O
CONH2
O N
NH
O
OMeO O
HN
O
(CH2)2H
-1.124
S6
O
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N
O
O
O
O
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O N
NH
O
OMeO OH
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4 Conclusions
The 3D-QSAR models presented here are powerful enough 
to suggest improvement in capuramycin derivatives. By 
combining 3D-QSAR and molecular docking studies, 
capuramycin derivatives as MraY inhibitors can be 
summarized as follows: (1) a bulky and electropositive 
substitute at the azepan-2-one moiety disfavors activity; 
(2) small and electropositive substituents at the nucleoside 
2’-OH improves bioactivity; (3) bulky substituents at 
the sugar hydroxyl may improve MraY inhibition. This 
information was used to design new capuramycin analogs 
with predicted activities higher than those used to derive 
the models. The synthetic compound S1 had relatively 
good anti-TB activity against both M. smegmatis MC2 155 
and Mycobacterium tuberculosis H37Rv. Thus, combined 
3D-QSAR and docking studies can be used as a guideline 
to design and predict new and more potent capuramycin 
analogs for tuberculosis therapy.
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